NCT07013214: DUAL-PD-RCT

Rehabilitation With Dual-task Exercises to Improve Balance in Patients With Parkinson's Disease

Recruiting now NA Last updated 12 March 2026

What this trial tests

NA trial testing Dual-Task Exercise in Parkinson Disease (PD), Postural Balance in 74 participants. Currently enrolling.

Timeline

7 July 2025

Primary endpoint
31 December 2025

1 April 2026

Quick facts

Lead sponsor	G. d'Annunzio University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	74
Start date	7 July 2025
Primary completion	31 December 2025
Estimated completion	1 April 2026
Sites	1 location across Italy

Drugs / interventions tested

• Dual-Task Exercise
• Standard Rehabilitation

Conditions studied

• Parkinson Disease (PD), Postural Balance — all drugs for Parkinson Disease (PD), Postural Balance →

Sponsor

G. d'Annunzio University

Who can join

30 and older, any sex, with Parkinson Disease (PD), Postural Balance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if a rehabilitative pathway based on dual-task exercise improves balance in patients with Parkinson's disease, compared to a traditional rehabilitation program. It will also investigate the reduction of fall risk, and improvement in autonomy and quality of life.

The main questions it aims to answer are:

* Does dual-task exercise improve balance more effectively than traditional rehabilitation in Parkinson's patients?
* Does dual-task exercise reduce the risk of falls?
* Does dual-task exercise improve patient autonomy in daily activities?
* Does dual-task exercise enhance the overall quality of life for Parkinson's patients? Researchers will compare a dual-task exercise program to a standard rehabilitation program. Both groups will receive 20 sessions, 2-3 times a week for two months, each lasting 45 minutes. The study will be double-blinded, meaning neither participants nor researchers involved in treatment administration and data collection will know group assignments. Randomization will be done using dedicated software to ensure unbiased group distribution.

Participants will:

* Have a confirmed diagnosis of Parkinson's disease (Movement Disorder Society criteria).
* Be in an early to moderate stage of the disease (Hoehn and Yahr score \< 3).
* Be over 30 years old.
* Be able to provide informed consent.
* Have a stable medication regimen for at least three months.

Exclusions include:

* Hoehn and Yahr score ≥3.
* Severe cognitive or psychiatric disorders (e.g., dementia).
* Use of interfering medications or treatments.
* Participation in other clinical trials.
* Pregnancy or breastfeeding.
* Need for medication changes during rehabilitation. Evaluations will be conducted at baseline (T=0), after rehabilitation (T=1), and at a two-month follow-up (T=2). Assessments will include the Tinetti Balance and Gait scales, Timed Up and Go (TUG) test, VAS pain scale, TAMPA Scale for Kinesiophobia, Global Perceived Effect (GPE), Barthel Index, EuroQoL-5D-5L, and ABC Scale. UPDRS, Hoehn and Yahr scale, and MOCA Scale will be administered only at baseline (T=0).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.